市場調查報告書
商品編碼
1378836
良性前列腺增生治療市場:2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測Benign Prostatic Hyperplasia Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球良性前列腺增生治療市場規模達到113億美元。展望未來, IMARC Group預計到2028年市場規模將達到155億美元,2022-2028年複合年成長率(CAGR)為5.4%。
良性攝護腺增生(BPH)或良性攝護腺肥大是指導致尿道阻塞的攝護腺非癌性腫大。這種情況會導致尿滯留困難、膀胱結石、因過度充盈而導致的尿失禁、膀胱敏感性增加以及尿路感染。 BPH 的一些常用治療替代方案包括處方藥、主動觀察或監測、單一藥物和聯合療法、植物療法以及微創 (MI) 和侵入性手術。這些手術通常透過電切鏡、射頻消融裝置、泌尿外科雷射、前列腺支架和植入物等設備進行。
全球泌尿系統疾病的盛行率不斷上升,是創造積極市場前景的關鍵因素之一。此外,老年人口的增加更容易患此類嚴重疾病,這也推動了市場的成長。醫療保健提供者使用 α 受體阻斷劑透過放鬆前列腺肌肉和控制患者血壓來控制 BPH。與此一致的是,大眾的健康意識和對可用治療替代方案的認知不斷提高也促進了市場的成長。此外,各種進步,例如作為一種有效治療方法的經尿道前列腺電切(TURP)的發展,也起到了其他生長誘導因素的作用。 TURP 是一種內視鏡電外科手術,涉及切除前列腺的一部分以減少異常生長引起的阻塞。其他因素,包括個人醫療保健支出能力的提高,以及醫療保健基礎設施的顯著改善,特別是在發展中國家,預計將進一步推動市場。
The global benign prostatic hyperplasia treatment market size reached US$ 11.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 15.5 Billion by 2028, exhibiting a growth rate (CAGR) of 5.4% during 2022-2028.
Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy refers to the non-cancerous enlargement of the prostate gland that causes blockage in the urethra. This condition causes difficulties in urine retention, bladder stones, incontinence due to overfilling, increased sensitivity of the bladder and infections in the urinary tract. Some of the commonly used treatment alternatives for BPH include prescription drugs, active observation or surveillance, mono drug and combined therapies, phytotherapies and minimally invasive (MI) and invasive surgeries. These surgeries are usually conducted through devices, such as resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents and implants.
The increasing prevalence of urological disorders across the globe represents one of the key factors creating a positive outlook for the market. Furthermore, the rising geriatric population, which is more susceptible to such critical ailments, is providing a boost to the market growth. Healthcare providers use alpha-blockers to manage BPH by relaxing the prostate muscles and controlling the blood pressure of the patient. In line with this, rising health consciousness and awareness among the masses regarding the available treatment alternatives are also contributing to the market growth. Additionally, various advancements, such as the development of transurethral resection of the prostate (TURP) as an effective treatment procedure, are acting as other growth-inducing factors. TURP is an endoscopic electrosurgical procedure that involves removing a portion of the prostate gland to reduce obstruction caused by the abnormal growth. Other factors, including rising healthcare expenditure capacities of individuals, along with significant improvements in the healthcare infrastructure, especially in the developing countries, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global benign prostatic hyperplasia treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on treatment type.
Drug Class
Alpha-Blockers
5-Alpha-reductase Inhibitors (5-ARIs)
Phosphodiesterase-5 Enzyme Inhibitors
Others
Minimally Invasive Surgeries
Transurethral Resection of the Prostate (TURP)
Transurethral Incision of the Prostate (TUIP)
Transurethral Microwave Thermotherapy (TUMT)
Robotic Surgeries
Prostatic Urethral Lifts
Others
Laser Therapy
Others
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.